UB-312 is under clinical development by Vaxxinity and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how UB-312’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UB-312 overview
UB-312 is under development for the treatment of Parkinson's disease and multiple system atrophy (MSA) and for dementia with Lewy bodies. The vaccine candidate is a synthetic alpha-synuclein (aSyn) peptide conjugated to a T-helper peptide. It is administered through intramuscular route.
Vaxxinity overview
Vaxxinity is a biotechnology company that enables the innovation of synthetic peptide vaccines to prevent or treat infectious diseases. It offers an innovative platform that has the power to activate different arms of the immune system selectively and to neutralize targets with high specificity. Vaxxinity is headquartered in Merritt Island, Florida, the US.
For a complete picture of UB-312’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.